(VIANEWS) – Invesco (IVZ), Surgery Partners (SGRY), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Invesco (IVZ)

14.8% sales growth and 9.96% return on equity

Invesco Ltd.

Invesco’s sales growth this year is anticipated to be 17.4% and 5.8% for next year.

Year-on-year quarterly revenue growth grew by 21.3%, now sitting on 6.51B for the twelve trailing months.

Volume

Today’s last reported volume for Invesco is 2172580 which is 46.23% below its average volume of 4040740.

Invesco’s sales growth for the next quarter is 14.8%. The company’s growth estimates for the present quarter and the next is 39.6% and 11.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.96%.

Volatility

Invesco’s last day, last week, and last month’s current intraday variation average was 0.30%, 0.97%, and 1.38%, respectively.

Invesco’s highest amplitude of average volatility was 3.49% (day), 2.51% (last week), and 2.84% (last month), respectively.

Invesco’s Stock Yearly Top and Bottom Value

Invesco’s stock is valued at $23.14 at 10:22 EST, way under its 52-week high of $29.71 and way above its 52-week low of $14.75.

Invesco’s Moving Average

Invesco’s worth is below its 50-day moving average of $25.20 and way below its 200-day moving average of $25.95.

Previous days news about Invesco(IVZ)

  • According to GlobeNewsWire on Saturday, 11 December, "The Nasdaq-100 Index® is the basis of the Invesco QQQ Trust (Nasdaq: QQQ) which aims to provide investment results that, before expenses, correspond with the Nasdaq-100 Index® performance. ", "In addition, options, futures and structured products based on the Nasdaq-100 Index® and the Invesco QQQ Trust trade on various exchanges."
  • Invesco Canada ltd. announces changes to several mutual funds. According to Benzinga on Thursday, 9 December, "You can also connect with Invesco on Twitter(@InvescoCanada), LinkedIn, Facebook, or through the Invesco Canada blog.", "Effective December 9, 2021, John Delano will become the portfolio manager of Invesco Global Growth Class and its investment strategies will change to utilize a distinct investment process seeking sustainable growth companies supported by long-term themes."
  • According to Benzinga on Saturday, 11 December, "European investors interested in FTEK LN can contact Invesco athttps://etf.invesco.com/gb/private/en/product/invesco-kbw-nasdaq-fintech-ucits-etf-acc/trading-information. "
  • According to Business Insider on Saturday, 11 December, "The bubble in speculative froth has popped," Hartnett said, highlighting that the ongoing breakdown in Ark Invest’s Disruptive Innovation fund is closely tracking the descent of Invesco during the 2000 dot-com unwind. "

2. Surgery Partners (SGRY)

11.8% sales growth and 4.46% return on equity

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States.

Surgery Partners’s sales growth this year is expected to be 20.2% and 10% for next year.

Year-on-year quarterly revenue growth grew by 12.7%, now sitting on 2.16B for the twelve trailing months.

Volume

Today’s last reported volume for Surgery Partners is 300494 which is 24.28% below its average volume of 396896.

Surgery Partners’s sales growth for the next quarter is 11.8%. The company’s growth estimates for the present quarter and the next is 122.2% and 83.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.46%.

Volatility

Surgery Partners’s last day, last week, and last month’s current intraday variation average was 1.74%, 1.43%, and 2.95%, respectively.

Surgery Partners’s highest amplitude of average volatility was 4.22% (day), 3.64% (last week), and 5.03% (last month), respectively.

Surgery Partners’s Stock Yearly Top and Bottom Value

Surgery Partners’s stock is valued at $43.74 at 10:22 EST, way below its 52-week high of $69.58 and way higher than its 52-week low of $24.20.

Surgery Partners’s Moving Average

Surgery Partners’s value is under its 50-day moving average of $44.50 and way under its 200-day moving average of $49.05.

3. United Therapeutics Corporation (UTHR)

10.1% sales growth and 13% return on equity

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

United Therapeutics Corporation’s sales growth this year is anticipated to be 14.4% and 10.6% for next year.

Year-on-year quarterly revenue growth grew by 17%, now sitting on 1.66B for the twelve trailing months.

Volume

Today’s last reported volume for United Therapeutics Corporation is 70444 which is 81.56% below its average volume of 382098.

United Therapeutics Corporation’s sales growth for the next quarter is 10.1%. The company’s growth estimates for the current quarter and the next is 64.4% and 460.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13%.

Volatility

United Therapeutics Corporation’s last day, last week, and last month’s current intraday variation average was 1.47%, 1.18%, and 1.17%, respectively.

United Therapeutics Corporation’s highest amplitude of average volatility was 4.60% (day), 3.68% (last week), and 3.06% (last month), respectively.

United Therapeutics Corporation’s Stock Yearly Top and Bottom Value

United Therapeutics Corporation’s stock is valued at $192.94 at 10:22 EST, way under its 52-week high of $216.90 and way higher than its 52-week low of $129.64.

United Therapeutics Corporation’s Moving Average

United Therapeutics Corporation’s worth is below its 50-day moving average of $193.57 and above its 200-day moving average of $190.08.

4. Lazard LTD (LAZ)

10% sales growth and 45.12% return on equity

Lazard Ltd, together with its subsidiaries, operates as a financial advisory and asset management firm in North America, Europe, Asia, Australia, and Central and South America.

Lazard LTD’s sales growth this year is expected to be 20.5% and 3.5% for next year.

Year-on-year quarterly revenue growth grew by 23.1%, now sitting on 3.07B for the twelve trailing months.

Volume

Today’s last reported volume for Lazard LTD is 561479 which is 25.56% above its average volume of 447177.

Lazard LTD’s sales growth for the next quarter is 10%. The company’s growth estimates for the current quarter and the next is a negative 10.8% and 13.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.12%.

Volatility

Lazard LTD’s last day, last week, and last month’s current intraday variation average was 0.13%, 0.79%, and 1.48%, respectively.

Lazard LTD’s highest amplitude of average volatility was 2.57% (day), 2.16% (last week), and 2.57% (last month), respectively.

Lazard LTD’s Stock Yearly Top and Bottom Value

Lazard LTD’s stock is valued at $0.60 at 10:22 EST, way below its 52-week low of $37.62.

Lazard LTD’s Moving Average

Lazard LTD’s worth is way below its 50-day moving average of $48.24 and way under its 200-day moving average of $46.06.